Sanofi: completes acquisition of Principia Biopharma
(CercleFinance.com) - On Monday Sanofi announced that it has completed the acquisition of Principia Biopharma Inc.
for 100 dollars per share, in cash.
"The Principia acquisition further strengthens our core areas of autoimmune and allergic diseases, giving us full control of tolebrutinib (SAR442168), as well as additional BTK inhibitors to further develop," said Paul Hudson, Sanofi's CEO.
"The Principia integration into Sanofi augments our small molecule research capabilities as we look to maintain leadership in the discovery and development of oral medicines for serious illnesses".
Copyright (c) 2020 CercleFinance.com. All rights reserved.
for 100 dollars per share, in cash.
"The Principia acquisition further strengthens our core areas of autoimmune and allergic diseases, giving us full control of tolebrutinib (SAR442168), as well as additional BTK inhibitors to further develop," said Paul Hudson, Sanofi's CEO.
"The Principia integration into Sanofi augments our small molecule research capabilities as we look to maintain leadership in the discovery and development of oral medicines for serious illnesses".
Copyright (c) 2020 CercleFinance.com. All rights reserved.